Inhibits Class I and II histone deacetylases (HDACs); induces accumulation of acetylated histones H2A, H2B, H3 and H4 in transformed cultured cells. Suppresses cell growth in a range of cancer cell lines; induces apoptosis in cutaneous T cell lymphoma cells in vitro. Activates autophagy.
SAHA is also offered as part of the Tocriscreen Plus, Tocriscreen Epigenetics Toolbox, Tocriscreen Library of FDA-Approved Compounds and Tocriscreen Stem Cell Toolbox. Find out more about compound libraries available from Tocris.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|ethanol||1.32||5mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 264.32. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.78 mL||18.92 mL||37.83 mL|
|5 mM||0.76 mL||3.78 mL||7.57 mL|
|10 mM||0.38 mL||1.89 mL||3.78 mL|
|50 mM||0.08 mL||0.38 mL||0.76 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Butler et al (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60 5165 PMID: 11016644
Leoni et al (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc.Natl.Acad.Sci.U.S.A 99 2995 PMID: 11867742
Marks and Breslow (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat.Biotechnol. 25 84 PMID: 17211407
Huangfu et al (2008) Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat.Biotechnol. 26 795 PMID: 18568017
Galluzzi et al (2017) Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat.Rev.Drug.Discov. PMID: 28529316
If you know of a relevant reference for SAHA, please let us know.
View Related Products by Product Action
Keywords: histone deacetylases HDACs inhibits inhibitors Class I Class II vorinostat anticancer antiproliferatives epigenetics proapoptotic Vorinostat Histone Deacetylases
1 Citation for SAHA
Citations are publications that use Tocris products. Selected citations for SAHA include:
Sarenac et al (2016) Single-cell analysis reveals IGF-1 potentiation of inhibition of the TGF-β/Smad pathway of fibrosis in humankeratocytes in vitro Scientific Reports 6 34373 PMID: 27687492
Do you know of a great paper that uses SAHA from Tocris? If so please let us know.
Literature in this Area
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Epigenetics Research Bulletin
Produced by Tocris and updated in 2014, the epigenetics research bulletin gives an introduction into mechanisms of epigenetic regulation, and highlights key Tocris products for epigenetics targets including:
- DNA Methyltransferases
- Histone Deacetylases
- Histone Demethylases
- Histone Methyltransferases
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.